Capofungin therapy for Aspergillus lung infection in a boy with chronic granulomatous disease.
Neutrophils of patients with chronic granulomatous disease (CGD) are profoundly defective in killing microorganisms. As in patients with chemotherapy-induced neutropenia, CGD patients are highly susceptible to life-threatening invasive Aspergillus infections, and conventional antimycotic treatment is not always successful. The new drug, caspofungin, was used to treat Aspergillus lung infection in one child with CGD.
Sallmann
Svea
S
Department of Pediatrics, University of Dresden, Germany.
Heilmann
Antje
A
Heinke
Frank
F
Kerkmann
Marie-Louise
ML
Schuppler
Markus
M
Hahn
Gabriele
G
Gahr
Manfred
M
Rösen-Wolff
Angela
A
Roesler
Joachim
J
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000302:isolation & purification; D000077336:Caspofungin; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D054714:Echinocandins; D005500:Follow-Up Studies; D006105:Granulomatous Disease, Chronic / Q000175:diagnosis*; D006801:Humans; D055666:Lipopeptides; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy*; D010455:Peptides; D010456:Peptides, Cyclic; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin